BioSpace News Archive

Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) announces that The Lancet published online positive results from a Phase 3 pivotal clinical trial of rimegepant Zydis® orally dissolving tablet (ODT) for the acute treatment of migraine.

The Galien Foundation today announced the 2019 Annual Prix Galien USA Award nominees. Counted among the global health innovation industry’s most prized honors, the Prix Galien Award recognizes outstanding biomedical and medical technology product achievement that improves the human condition.

ESSA Pharma Inc. (“ESSA” or “the Company”) (NASDAQ: EPIX; TSX-V: EPI), a pharmaceutical company focused on the developing novel therapies for the treatment of prostate cancer, announced today the appointment of Dr. Alessandra Cesano, M.D., PhD as Chief Medical Officer (“CMO”).

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that it plans to report its financial results for its fiscal third quarter ended June 30, 2019 after the U.S. markets close on August 6, 2019.

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors provided an operational update and released financial results for the fiscal year ended April 30, 2019.

Inscopix today announced a new research collaboration with Biogen to research and develop a new class of therapies for chronic pain.

Bracco Diagnostics Inc., the U.S. subsidiary of Bracco Imaging S.p.A., one of the world’s leading companies in the diagnostic imaging business, shares the results of a new prospective clinical study of the use of ultrasound enhancing agents (UEAs) in transthoracic echocardiography reaffirming the proven safety profile of its LUMASON ultrasound enhancing agent.

Kymera Therapeutics Inc., a biotechnology company advancing the field of targeted protein degradation to create breakthrough therapies for previously untreatable diseases, today announced key leadership transitions

Hexion Inc. (“Hexion” or the “Company”) is serving as the Start Line sponsor of 2019 American Heart Association (“AHA”) Central Ohio Heart Walk on August 24 in downtown Columbus.

Acquisition adds key platform supporting Boehringer Ingelheim’s focus on patients with difficult-to-treat gastrointestinal and lung cancers